Ticker

Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times Skyrizi in Phase 1, targeting the $30B psoriasis market. ORKA-001 and ORKA-002 aim for best-in-class efficacy with dramatically less frequent dosing, potentially shifting the treatment paradigm for chronic skin diseases. Phase 2a EVERLAST-A results for ORKA-001 are expected in 2H26; meaningful revenue is not anticipated until 2031,…

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:

Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the transaction, the insider owned 1,518 shares of the company's

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif.,…

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P.